| abstract |
The present invention provides a period of 24, 60 or 90 days over predose with little or no reduction in serum HDL cholesterol and / or little or no measurable effect on liver function as measured by ALT and AST assays. Antigen-binding of a human antibody or human antibody that specifically binds to or inhibits human shear protein convertase subtilisin / chexin type 9 (hPCSK9), characterized by the ability to reduce serum LDL cholesterol by 40-80% It's about fragments. |